PUBLISHED IN: 24-09-2026
Fibroaging is Dr. Scott King's clinical term for the age-related buildup of muscle and fascia adhesion — connective tissue that becomes progressively denser, less organized, and less mobile the longer it goes unaddressed. It is not a diagnosis you will find in a textbook. It is a name for a pattern Dr. King sees constantly in practice: stiffness patients and their previous providers wrote off as "just getting older," which is actually identifiable, treatable adhesion.
Musculoskeletal fibroaging describes how connective tissue changes as adhesion accumulates over decades rather than resolving. Healthy fascia and muscle tissue glide against each other in organized, parallel fiber patterns. When an area is injured, overused, or simply under-moved for long enough, the body lays down repair tissue in a disorganized crosshatch instead — and if nothing intervenes, each subsequent cycle of minor strain and incomplete repair adds another layer. Over years, that process compounds into the dense, restricted tissue Dr. King calls fibroaging: not a single event, but a slow accumulation that most people and many providers mistake for an inevitable part of getting older.
The underlying biology is real and published; the musculoskeletal application is Dr. King's own clinical framework built on it. "Fibroageing" was named in a 2021 review in the journal Ageing Research Reviews as the general tendency toward fibrosis that comes with aging extracellular matrix — the same stiffening-feedback-loop mechanism implicated in age-related fibrosis of the lungs, liver, kidneys, and heart. It's significant enough as a research area that Harvard Stem Cell Institute runs a dedicated Aging & Fibrosis research initiative, the Harvard Fibrosis Network, uniting investigators across organs specifically to find what's common to fibrotic disease as the body ages — evidence this is an active, cross-disciplinary research priority, not a fringe idea. Dr. King uses "musculoskeletal fibroaging" to describe how that identical process plays out in muscle and fascia specifically: as adhesion, not organ scarring, and — unlike fibrosis in those other organs — directly reachable and treatable with hands-on and device-assisted soft-tissue therapy.
At the cellular level, fibroaging follows a fibrotic feedback loop that aging-biology researchers have described across the body, not just in muscle. The 2021 Ageing Research Reviews paper that introduced the term "fibroageing" describes how extracellular matrix molecules stiffen with age through glycation and crosslinking, and how that stiffness itself activates further fibrotic signaling, creating a self-reinforcing loop tied to cellular senescence, the senescence-associated secretory phenotype (SASP), and YAP/TAZ mechanotransduction. The same authors note this loop is why fibrosis becomes far more common with age across organs — idiopathic pulmonary fibrosis, for example, is uncommon before 50 and rises sharply after 60.
A January 2026 review in Frontiers in Immunology traces the muscle-specific version of this mechanism: reactive oxygen species upregulate TGF-β1 signaling, which drives fibro-adipogenic progenitor cells (FAPs) to differentiate into myofibroblasts — the cells responsible for excess collagen deposition in muscle tissue. As the surrounding matrix stiffens from that collagen buildup, the stiffness itself triggers further fibrotic signaling.
Senescent cells make this worse. A March 2026 paper in Endocrinology and Metabolism found that senescent fibro-adipogenic progenitors secrete TGF-β as part of their SASP, which stimulates both themselves and neighboring fibroblasts to overproduce collagen — directly aggravating fibrosis. This is the same senescence-driven mechanism discussed in our post on shockwave therapy and cellular aging: the same ECM-stiffening feedback loop described at the whole-body level, with muscle and fascia simply being where Dr. King sees it accumulate as adhesion — dense, mechanically loaded daily, and rarely examined closely enough to catch early.
Musculoskeletal stiffness affects the majority of adults, at every age, and gets substantially worse after 60. A 2021 study in Musculoskeletal Care measured stiffness in 282 healthy adults with no rheumatological diagnosis and found that over half reported meaningful stiffness across every age group — but adults 60 and older scored nearly double the overall median, and were the only group where a majority also reported real physical or functional impact.
That gap is the clinical signature of fibroaging: stiffness that started as an occasional nuisance becomes a load-bearing problem specifically once adhesion has had enough years to compound.
No — fibroaging is a treatable process that happens to correlate with age, not an unavoidable consequence of it. The distinction matters because it changes what a patient should do about it. "Normal aging" is typically treated as something to accept or work around. Fibroaging is adhesion: identifiable by hand, driven by a specific and increasingly well-understood cellular mechanism, and directly treatable with the same soft-tissue techniques and shockwave-based therapies that treat adhesion at any age. Two people the same age can have very different amounts of fibroaged tissue depending on injury history, activity patterns, and how much of that adhesion was addressed versus left to accumulate.
The clearest signs are stiffness that is worse first thing in the morning or after sitting, a gradual loss of range of motion in the same one or two areas over months or years, and tissue that feels dense, ropey, or "stuck" rather than simply sore when pressed. Patients often describe it as an area that "never quite loosens up anymore" the way it used to after a warmup, or pain that shows up doing the same activities that used to feel fine. Because it accumulates slowly, fibroaging is easy to attribute to age rather than to the specific, palpable adhesion driving it — which is exactly why a hands-on evaluation matters more than a general assumption about getting older.
Yes. Fibroaging responds to the same adhesion-focused treatment approach used for soft-tissue restrictions at any age — the tissue itself doesn't become fundamentally untreatable with time, it simply requires addressing years of accumulated adhesion rather than a single recent strain. Dr. King treats fibroaging with a combination of manual soft-tissue work and device-assisted therapy, including EMTT for deeper, harder-to-reach adhesion and shockwave therapy, which recent research shows directly reduces cellular senescence markers — targeting one of the underlying drivers of the fibrotic cycle, not just the symptom of stiffness on top of it. The Musculoskeletal Fibroaging section of our adhesion page covers how this fits into Dr. King's broader clinical framework for identifying and treating adhesion.
If stiffness in the same area has been building for years rather than resolving, that pattern is worth a hands-on evaluation rather than an assumption about age. Dr. King's Centennial clinic, serving the Denver Tech Center area, evaluates musculoskeletal fibroaging directly — assessing which tissue has become genuinely restricted versus simply older — and builds a treatment plan around the adhesion actually present. Request an appointment to have it evaluated.
Just west off I-25/Orchard in Greenwood Village/Denver Tech Center.